REG - Genedrive PLC - Board changes

GenedriveAnnouncement

11/09/2023 14:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230911:nRSK0533Ma&default-theme=true

RNS Number : 0533M  Genedrive PLC  11 September 2023

 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY GENEDRIVE PLC
TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE
REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK LAW BY VIRTUE OF THE
EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR").

 

UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW
CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

genedrive plc

("genedrive" or the "Company")

 

Board changes

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company
announces the appointment of James Cheek as Chief Executive Officer ("CEO")
and a Director of the Company. James will take up the positions today and will
succeed David Budd, who has notified the Company of his intention to step down
from the role with immediate effect.

 

James brings extensive commercial and operational experience at a senior level
through a successful career with established diagnostic companies such as
Cepheid, Beckman Coulter, and Roche Diagnostics, as well as serving as an
executive board member of the British In Vitro Diagnostics Association
(BIVDA). The Board believes James' experience, especially his extensive
involvement in selling into the NHS, will be valuable as the Company expands
its commercial footprint and opportunities within the UK and more widely.

 

We are also pleased to announce the appointment of Dr Gino Miele, Chief
Scientific Officer at genedrive, to the Board as an Executive Director, with
immediate effect. Gino has considerable experience in the development of
molecular diagnostic technologies and systems and has been the R&D
Director at genedrive since 2015 and its predecessor Epistem since 2011.
Prior to that Gino has held associate director positions in personalised
medicine at Wyeth and Pfizer. Gino has been a key driver in the development of
the genedrive® system and the recent menu of pharmacogenetic tests.

 

Ian Gilham, Chairman of genedrive, commented: "I am pleased to welcome James
to the Company and look forward to working with him on the continued execution
of our plans in commercialising our innovative Point-of-Care molecular
diagnostic platform and tests. The focus of the Board remains on the
development and commercialisation of novel Point-of-Care Molecular Diagnostic
opportunities available to the Company. James' appointment underlines the
Board's commitment to the ongoing successful commercial execution of the
Company's innovative portfolio. I would also like to welcome Gino to the Board
and look forward to his ongoing contributions to the Company going forwards.

 

"I would also like to thank David for his dedication and leadership over the
past seven years, as he transitioned the Company from a Contract Research
Organisation to being an innovator in the development of molecular diagnostics
for use at Point-of-Care.  David has agreed to support James as required
during his transition into his new role."

 

James Cheek, incoming CEO of genedrive commented: "I am very pleased to be
joining genedrive at such a pivotal time for the launch and commercialisation
of new rapid Point-of-Care pharmacogenetic tests for antibiotic induced
hearing loss in children and optimal treatment selection for stroke patients
on the genedrive® platform. I look forward to working with the outstanding
individuals at genedrive, to deliver solutions that our customers need."

 

The following information is disclosed pursuant to Schedule Two, paragraph (g)
of the AIM Rules for Companies in respect of James Cheek:

 

Full name and age: James Bernard Cheek (aged 56)

 

James Cheek does not currently hold any ordinary shares in genedrive plc.

 

Current Directorships or Partnerships:

 

None

 

Past Directorships of Partnerships:

 

Cepheid UK Limited

The British In Vitro Diagnostics Association (BIVDA)

 

No further information in connection with James Cheek's appointment is
required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules
for Companies.

 

The following information is disclosed pursuant to Schedule Two, paragraph (g)
of the AIM Rules for Companies in respect of Dr. Gino Miele:

 

Full name and age: Dr. Gino Miele (aged 53)

 

Gino Miele and his wife hold 66,979 ordinary shares in genedrive plc.

 

Current Directorships or Partnerships:

 

Cytomos Limited

 

Past Directorships of Partnerships:

 

GMDX Limited

 

No further information in connection with Dr. Gino Miele's appointment is
required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules
for Companies.

 

 

 

 

 

 

 

 

For further details please contact:

 genedrive plc                                       +44 (0)161 989 0245
 Russ Shaw: CFO

 Peel Hunt LLP (Nominated Adviser and Joint Broker)  +44 (0)20 7418 8900
 James Steel / Patrick Birkholm

 finnCap (Joint Broker)                              +44 (0)20 7220 0500
 Geoff Nash

 Walbrook PR Ltd (Media & Investor Relations)        +44 (0)20 7933 8780 or genedrive@walbrookpr.com
                                                     (mailto:genedrive@walbrookpr.com)
 Paul McManus / Anna Dunphy                          +44 (0)7980 541 893 / +44 (0)7876 741 001

 

About genedrive plc (http://www.genedriveplc.com
(http://www.genedriveplc.com/) )

genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and robust point
of need molecular diagnostics platform for use in patient stratification
(genotyping), pathogen detection and other indications in emergency care.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABXGDCUBBDGXB